Celon Pharma (WAR:CLN) Other Stockholders Equity: zł4.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:CLN Celon Pharma SA WAR:CLN
21 GF Score
Price zł20.90
! 3 Warning Signs
View Full Analysis

What is Celon Pharma Other Stockholders Equity?

Celon Pharma WAR:CLN -0.95% 21 Other Stockholders Equity is zł4.0 Mil as of Mar. 2026. GuruFocus rates WAR:CLN with a GF Score™ of 21/100. The stock has 3 warning signs investors should review.

Celon Pharma's Other Stockholders Equity for the quarter that ended in Mar. 2026 was zł4.0 Mil.

Celon Pharma's quarterly Other Stockholders Equity increased from Sep. 2025 (zł2.0 Mil) to Dec. 2025 (zł357.9 Mil) but then declined from Dec. 2025 (zł357.9 Mil) to Mar. 2026 (zł4.0 Mil).

Celon Pharma's annual Other Stockholders Equity increased from Dec. 2023 (zł5.9 Mil) to Dec. 2024 (zł439.8 Mil) but then declined from Dec. 2024 (zł439.8 Mil) to Dec. 2025 (zł357.9 Mil).

Celon Pharma Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Celon Pharma's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma Other Stockholders Equity Chart

Celon Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.07 7.23 5.85 439.82 357.86

Celon Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.94 1.59 2.01 357.86 4.01
WAR:CLN
21GF Score
Celon Pharma SA WAR:CLN
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celon Pharma Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of zł4.0 Mil mean?
Celon Pharma (WAR:CLN) has a Other Stockholders Equity of zł4.0 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Celon Pharma and its competitors.
Is Celon Pharma's Other Stockholders Equity too high?
Celon Pharma's current Other Stockholders Equity is zł4.0 Mil. Overall, Celon Pharma has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Other Stockholders Equity compare to ZTS and UTHR?
Celon Pharma's Other Stockholders Equity of zł4.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Celon Pharma and its competitors. Celon Pharma's current Other Stockholders Equity is zł4.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Celon Pharma (WAR:CLN) has a current Other Stockholders Equity of zł4.0 Mil. The current Other Stockholders Equity is zł4.0 Mil. Celon Pharma's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current Other Stockholders Equity is zł4.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celon Pharma Business Description

Other Exchanges 8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
21GF Score

Get the complete analysis for WAR:CLN

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł20.90
Price